drugset / Trial / NCT07657052

A Multicenter, Open-label Study Evaluating the Long-term Safety and Efficacy of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT07657052 ↗

Enrolling by invitation 26 enrolled S-INFINITY Pharmaceuticals Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label study to evaluate the long-term safety and efficacy of XH-S003 capsules in PNH patients. About 26 PNH patients who had received and completed XH-S003 study treatment will be enrolled to take XH-S003 capsules orally according to protocol. Eligible subjects can maintain XH-S003 treatment until the end of the study.

Timeline

Start
2025-08-15
Primary completion
2029-09-30
Completion
2029-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject XH-S003 Unknown — Oral